SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G - Elevation Oncology, Inc. (0001783032) (Subject)

SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress 2024 (ESMO-IO 2024) -- -- Expect to initiate dosing in combination portion of the Phase 1 trial of EO-3021 in 4Q 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 4Q 2024 -- BOSTON, Nov. 6, 2024 /PRNewswire/ -

BOSTON, Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed on or after prior therapy. "We are delighted to receive Fast Track designation for EO-3021, which marks an enc

BOSTON, Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET. A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com. About Elevation Oncology, Inc. Eleva

-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings -- -- On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 by mid-3Q 2024, with additional data in 1H 2025 -- BOSTON, June 27, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery

BOSTON, May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET. A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com. About Elevation Oncology, Inc. Elevation Oncology is an innovat

-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 -- -- Raised $44.2 million year-to-date through ATM facility, extending cash runway into 2026 -- BOSTON, May 2, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today a

-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program.  The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. "We are pleased to share the first preclinical proof-of-concept data for our HER3-ADC program,

--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 ---- Preclinical proof-of-concept data for HER3-ADC program to be presented at AACR Annual Meeting; plan to nominate development candidate in 2024 –-- Raised approximately $17.0M in net proceeds through at-the-market (ATM) facility and refinanced debt facility with K2 Health Ventures; cash runway into the fourth quarter of 2025 -- BOSTON, March 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat pati

8-K - Elevation Oncology, Inc. (0001783032) (Filer)

10-Q - Elevation Oncology, Inc. (0001783032) (Filer)

8-K - Elevation Oncology, Inc. (0001783032) (Filer)

10-Q - Elevation Oncology, Inc. (0001783032) (Filer)

8-K - Elevation Oncology, Inc. (0001783032) (Filer)

8-K - Elevation Oncology, Inc. (0001783032) (Filer)

EFFECT - Elevation Oncology, Inc. (0001783032) (Filer)

424B3 - Elevation Oncology, Inc. (0001783032) (Filer)

S-3 - Elevation Oncology, Inc. (0001783032) (Filer)

8-K - Elevation Oncology, Inc. (0001783032) (Filer)

GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o

JMP Securities analyst Silvan Tuerkcan reiterates Elevation Oncology (NASDAQ:ELEV) with a Market Outperform and maintains $7 price target.

JMP Securities analyst Silvan Tuerkcan reiterates Elevation Oncology (NASDAQ:ELEV) with a Market Outperform and maintains $7 price target.

Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting

Piper Sandler analyst Biren Amin initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Overweight rating and announces Price Target of $10.

Stephens & Co. analyst Sudan Loganathan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Overweight rating and announces Price Target of $8.

Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ:HROW) shares rose 13.5% to $13.7. The market value of their outstanding shares is at $484.7 million. As per the press release, Q1 earnings came out today. Vaxart (NASDAQ:VXRT) stock moved upwards by 12.19% to $0.92. The market value of their outstanding shares is at $162.6 million. The company's, Q1 earnings came out today. Modular Medical (NASDAQ:MODD) shares moved upwards by 7.77% to $1.94. The market value of their outstanding shares is at $60.1 million. Gossamer Bio (NASDAQ:GOSS) stoc

Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $8 price target.

Gainers Emergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday. Nuwellis (NASDAQ:NUWE) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million. Syra Health (NASDAQ:SYRA) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million. Titan Pha

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

4 - Elevation Oncology, Inc. (0001783032) (Issuer)

Piper Sandler initiated coverage of Elevation Oncology with a rating of Overweight and set a new price target of $10.00

Stephens initiated coverage of Elevation Oncology with a rating of Overweight and set a new price target of $8.00

JMP Securities initiated coverage of Elevation Oncology with a rating of Mkt Outperform and set a new price target of $7.00

SVB Securities upgraded Elevation Oncology from Market Perform to Outperform and set a new price target of $8.00 from $5.00 previously

Wedbush reiterated coverage of Elevation Oncology with a rating of Outperform and set a new price target of $21.00 from $27.00 previously

HC Wainwright & Co. initiated coverage of Elevation Oncology with a rating of Buy and set a new price target of $12.00

JP Morgan initiated coverage of Elevation Oncology with a rating of Overweight and set a new price target of $24.00

Wedbush initiated coverage of Elevation Oncology with a rating of Outperform and set a new price target of $27.00

Cowen & Co. initiated coverage of Elevation Oncology with a rating of Outperform

SVB Leerink initiated coverage of Elevation Oncology with a rating of Outperform and set a new price target of $20.00

BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023Announced pipeline prioritization and realignment of resources focused on advancing EO-3021Joseph Ferra, Chief Financial Officer, appointed Interim Chief Executive Officer Cash runway extended into the fourth quarter of 2024NEW YORK, March 9, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quart

Prioritizing the development of EO-3021, a potential best-in-class ADC targeting Claudin18.2, and additional pipeline programs including those through its existing partnership with Caris Life SciencesPlanning to present EO-3021 preclinical proof-of-concept data at a major medical conference in the first half of 2023, and initiate Phase 1 trial in the US in the second half of 2023; CSPC is actively recruiting patients in an ongoing Phase 1 clinical trial in ChinaPausing further investment in the clinical development of seribantumab; intends to pursue further development only in collaboration with a partnerJoseph Ferra, CFO, appointed as Interim CEO; Shawn Leland has resigned as CEO and member

Initial seribantumab clinical data from Phase 2 CRESTONE study selected for oral presentation at ASCO 2022 David Dornan, PhD appointed Chief Scientific Officer, bringing deep oncology R&D and drug development expertise to further Company's continued focus on future pipeline expansion throughout 2022 and beyondCash, cash equivalents and marketable securities totaling $132.1 million expected to fund current operations into the fourth quarter of 2023NEW YORK, May 5, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced financial resul

NEW YORK, March 14, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the appointment of David Dornan, Ph.D. as the Company's Chief Scientific Officer. "We are thrilled to welcome David, a seasoned industry R&D leader, with broad expertise in oncology drug development, who will greatly contribute to helping us build a leading precision oncology company and expand our product pipeline beyond seribantumab," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology. "As our first CSO, David bring

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the appointment of Valerie M. Jansen, M.D., Ph.D., as Chief Medical Officer. Dr. Jansen was promoted from her prior role as Vice President, Clinical Development. "Dr. Jansen has made significant contributions to Elevation Oncology's vision since her arrival at the Company earlier this year and we are thrilled to have her take on this role within the Elevation Oncology executive team," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of El